Recent Updates
Recently added Catalysts
AGEN Negative Sentiment Score: 30/100

AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline

Key Takeaway: Bernstein Liebhard LLP has issued a reminder to investors of Agenus Inc. regarding a deadline connected to a securities fraud class action lawsuit. The lawsuit, filed in the District of Massachusetts, claims that Agenus made misleading statements regarding its treatment for metastatic colorectal cancer. Investors who purchased shares from January 23, 2023, to July 17, 2024, are urged to review their rights and consider participating in the case. A lead plaintiff must file paperwork by November 5, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • A securities fraud class action lawsuit has been filed against Agenus.
  • The lawsuit alleges misrepresentations by the company concerning its investigational therapy.
  • Investors who purchased shares during the specified period may have suffered financial losses.
  • There is a specific deadline for investors to act as lead plaintiffs in the lawsuit.

Full Press Release Details

NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
Do you, or did you, own shares of Agenus Inc. (NASDAQ: AGEN)?
Did you purchase your shares between January 23, 2023 and July 17, 2024, inclusive?
Did you lose money in your investment in Agenus Inc.?
Do you want to discuss your rights?
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
If you purchased or acquired Agenus securities, and/or would like to discuss your legal rights and options please visit Agenus Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
A lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of investors who purchased or acquired the securities of Agenus between January 23, 2023 and July 17, 2024, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers.
According to the lawsuit, Agenus made misrepresentations concerning the development of the Company’s investigational therapy for the treatment of patients with metastatic colorectal cancer.
If you wish to serve as lead plaintiff for the Class, you must file papers by November 5, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the deadline for the Agenus class action lawsuit?

The deadline for filing papers to serve as lead plaintiff is November 5, 2024.

What period does the Agenus class action cover?

The class action covers purchases made from January 23, 2023, to July 17, 2024.

What allegations are made against Agenus Inc.?

The lawsuit alleges that Agenus made misrepresentations about its cancer therapy's development.

Do I have to pay any fees for representation?

No fees or expenses are required from shareholders as representation is on a contingency basis.

Who can I contact for more information?

For more details, contact Peter Allocco at pallocco@bernlieb.com or call (212) 951-2030.

Last updated: Oct 7, 2024